In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AnaptysBio, Inc.

http://www.anaptysbio.com/

Latest From AnaptysBio, Inc.

Novartis’s Cosentyx Secures Qualified Win In Hidradenitis Suppurativa

The Swiss major’s Cosentyx has succeeded in two trials for the debilitating skin condition but there are concerns that the data may not be sufficient to shift AbbVie’s Humira off the top spot for treatment.

Clinical Trials Strategy

Boehringer’s Spesolimab Wins First Approval In Rare Skin Condition

The German firm’s monoclonal antibody has received a US thumbs-up for a severe skin disease with high unmet need but it must address diagnostic and educational hurdles.

Approvals Inflammation

AnaptysBio’s Imsidolimab Meets Yet Another Failure

The company is discontinuing the drug’s development in hidradenitis suppurativa after a Phase II flop, leaving GPP as the only viable indication, for which it is planning to out-license the drug.

Clinical Trials Business Strategies

Gilead Grabs MiroBio's Checkpoint Agonists For $405m

Just over a month after raising $97m in a series B round, Oxford University spinout MiroBio and its immune checkpoint agonists have been snapped up by Gilead Sciences. 

M & A Immune Disorders
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register